Compare Forgent Power Solutions Inc. Class A Common Stock (FPS) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Forgent Power Solutions Inc. Class A Common Stock vs GSK plc — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $32.19 (market cap $9.93B), while GSK plc trades at $47.87 (market cap $92.78B). The key difference: GSK plc is far larger — about 9.3× Forgent Power Solutions Inc. Class A Common Stock's market cap, and GSK plc pays a 3.92% dividend while Forgent Power Solutions Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and GSK plc for 93 Days on average.
| FPS | GSK | |
|---|---|---|
Market Cap | $9.93B | $92.78B |
Volume | 7,516,726 | 5,756,402 |
Sector | Industrials | Health |
52-Week High | $64.59 | $61.18 |
52-Week Low | $27.97 | $43.24 |
Typical Hold Time | 0 Days | 93 Days |
Enterprise Value | $10.54B | $112.77B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Forgent Power Solutions Inc. Class A Common Stock
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
